Our research shows that the infiltration status of three tumor-infiltrating immune cell types, CD8+ T cells, neutrophils, and dendritic cells, is significantly associated with the mutational status of the TP53 gene and may impact survival outcomes of immunotherapy. This evidence concerns the gene CD8A and neoplasm.